Get the Stockscreener App
124.15
1.00%
1.23
After Hours:
124.15
Jazz Pharmaceuticals Plc stock is traded at $124.15, with a volume of 1.50M.
It is up +1.00% in the last 24 hours and down -13.50% over the past month.
See More
Previous Close:
$122.92
Open:
$121.46
24h Volume:
1.50M
Relative Volume:
1.81
Market Cap:
$7.68B
Revenue:
$3.99B
Net Income/Loss:
$463.16M
P/E Ratio:
17.49
EPS:
7.1
Net Cash Flow:
$1.10B
1W Performance:
-12.58%
1M Performance:
-13.50%
6M Performance:
+11.44%
1Y Performance:
+3.10%
1-Day Range:
$120.61
$124.68
1-Week Range:
$120.61
$142.42
52-Week Range:
$99.06
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
124.15 | 7.68B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
JAZZ or ARGX: Which Is the Better Value Stock Right Now? - Yahoo Finance
Teacher Retirement System of Texas Buys 2,346 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Is Jazz Pharmaceuticals (JAZZ) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
10 Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - Eagle-Tribune
Jazz Pharma Reveals Growth Strategy: Key Updates Coming at Major Healthcare Conference - Stock Titan
Dravet Syndrome Market Expected to Experience Major Growth - openPR
Is Jazz Pharmaceuticals plc (JAZZ) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR
Axsome's ADHD drug meets main goal in late-stage study - Marketscreener.com
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Jazz strikes the chord with $935m Chimerix acquisition - Xconomy
Based On Its ROE, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A High Quality Stock? - simplywall.st
Zacks.com featured highlights include MPLX LP, Leidos, Jazz Pharmaceuticals, Fortinet and Pilgrim's Pride - Yahoo Finance
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results - GlobeNewswire Inc.
Akari Therapeutics Appoints Biotechnology Industry Leader, - GlobeNewswire
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - Yahoo Finance
Interesting JAZZ Put And Call Options For October 17th - Nasdaq
Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect? - Yahoo Finance
Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting - PR Newswire
New Trial Results: 70% Patient Success Rate for Jazz Pharma's Sleep and Seizure Drugs - Stock Titan
Jazz Inks Insurer Class Deal As Xyrem Antitrust Trial Nears - Law360
JAZZ or ILMN: Which Is the Better Value Stock Right Now? - Yahoo Finance
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition? - Yahoo Finance
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock - Yahoo Finance
Jazz Pharmaceuticals EVP sells shares worth $332,604 By Investing.com - Investing.com South Africa
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant - Yahoo Finance
Jazz Pharmaceuticals and Boston Beer Company have been highlighted as Zacks Bull and Bear of the Day - Zacks Investment Research
Bull of the Day: Jazz Pharmaceuticals (JAZZ) - Yahoo Finance
Insider Sell: Bruce Cozadd Sells 6,500 Shares of Jazz Pharmaceuticals PLC (JAZZ) - GuruFocus.com
Bull Of The Day: Jazz Pharmaceuticals (JAZZ) - Barchart
H.C. Wainwright lifts Jazz stock target to $217, maintains Buy By Investing.com - Investing.com UK
Charles Schwab Investment Management Inc. Grows Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
HC Wainwright Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - Defense World
DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga India
Victory Capital Management Inc. Increases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded at UBS Group - Defense World
Robert Iannone Sells 7,080 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock - Defense World
Morgan Stanley Reiterates “Overweight” Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - Defense World
Truist Financial Boosts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $230.00 - Defense World
UBS Upgrades Jazz Pharmaceuticals (JAZZ) - Nasdaq
Jazz Pharmaceuticals Plc to Host Earnings Call - ACCESS Newswire
Needham & Company LLC Reiterates Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - Defense World
UBS Upgrades Jazz Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $179 From $145 - Marketscreener.com
UBS raises Jazz Pharmaceuticals stock rating to Buy, target to $179 By Investing.com - Investing.com UK
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals - Nasdaq
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More - Nasdaq
Jazz Pharmaceuticals at TD Cowen Conference: Strategic Growth in Focus By Investing.com - Investing.com UK
Truist Raises PT on Jazz Pharmaceuticals to $230 From $220 on Heels of Announced Purchase of Chimerix, Keeps Buy Rating - Marketscreener.com
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):